Amneal announces the approval and launch of generic carafate

Amneal pharmaceuticals, inc. announced that it has received final u.s. food and drug administration approval on its abbreviated new drug application for a generic version of carafate oral suspension, 1 g/10 ml. amneal has immediately initiated commercialization activities.
AMRX Ratings Summary
AMRX Quant Ranking